MedPath

Flaxseed on insulin resistance in ulcerative colitis

Early Phase 1
Conditions
Men and women aged 55-18 years with ulcerative colitis (mild to moderate).
Ulcerative colitis
Registration Number
IRCT20201229049878N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
64
Inclusion Criteria

Age 18 to 55 years
Body Mass Index (BMI) 18.5 and above
Histopathologically confirmed ulcerative colitis
The duration of ulcerative colitis should be at least 3 months.
No change in the type and dose of medication used during the last 3 months
Patients are in the active stage (mild to moderate) of the disease.
Willingness to cooperate in this project

Exclusion Criteria

Other intestinal diseases and disorders, autoimmune diseases, cancer, inflammatory and infectious diseases
Diabetes or hyperlipidemia (taking drugs that stimulate insulin secretion (such as glibenclamide) or drugs that affect lipid profile (such as statins))
History of gastrointestinal surgery
Having other gastrointestinal diseases or gastrointestinal surgery during the study
Pregnancy and lactation
Use of anti-TNF alpha or immunomodulatory drugs (methotrexate and prednisolone) at or during the study

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath